Epcoritamab
Epcoritamab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Large B Cell Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
0 项
已进入 III/IV 期
24 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- Yazeed Sawalha
- Reid Merryman, MD
- National Research Center for Hematology, Russia
- Taylor Brooks
- M.D. Anderson Cancer Center
- Hospital Universitario Dr. Jose E. Gonzalez
- Australasian Leukaemia and Lymphoma Group
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、西班牙、Russia、Mexico、澳大利亚、英国、Argentina、奥地利、比利时、Bulgaria、加拿大、Greece
正在招募患者的 Epcoritamab 研究
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
I 期 / II 期招募中美国NCT06536049Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
II 期招募中西班牙NCT07126236Epco, Zanu, Ritux for R/R FL or MZL
II 期招募中美国NCT06563596Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas
II 期招募中RussiaNCT07883135Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
I 期招募中美国NCT06447376Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
I 期 / II 期招募中美国NCT07283679Low Dose Epcoritamab Plus GemOx in R/R DLBCL
II 期招募中MexicoNCT07451652Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
II 期招募中澳大利亚NCT06287398Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
II 期招募中英国NCT05848765Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
II 期招募中美国NCT06723457Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
I 期招募中美国NCT06672705MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
II 期招募中澳大利亚NCT06414148Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
II 期招募中美国NCT06919939Epcoritamab in Previously Treated WM
II 期招募中美国NCT06510491A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
I 期招募中美国NCT07082868Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
不适用招募中Argentina澳大利亚奥地利比利时NCT06830759Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
II 期招募中美国NCT07108998Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
II 期招募中美国NCT07097363Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
II 期招募中美国NCT07365306Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
II 期招募中美国NCT06796998Epcoritamab-CAR T Cells for Large B-cell Lymphomas
II 期招募中美国NCT06458439Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
I 期 / II 期招募中澳大利亚比利时丹麦德国NCT05791409External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
I 期招募中美国NCT07528352A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
I 期 / II 期招募中美国Chile中国法国NCT06090539
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。